Navigation Links
Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
Date:12/6/2010

4;BSignaling and Induces Apoptosis in Multiple Myeloma Cells

Session: Myeloma – Pathophysiology and Preclinical Studies, excluding Therapy: Multiple Myeloma – Molecular Target-Based Therapy

Location: Orange County Convention Center, 314

About CK2 and CX-4945

Protein kinase CK2 has emerged as a validated drug target for cancer therapy due to its dysregulation andoverexpression in tumors and its regulatory roles in cell cycle control, DNA damage repair, and in the PI3K/Akt, JAK/STAT, IL-6 and NF-κB signaling cascades.  These pathways have specific relevance in multiple myeloma progression and high levels of CK2 overexpression characterize the disease.  CX-4945 is a potent and highly selective, small molecule inhibitor of CK2 and is currently under evaluation as an orally administered single agent in a Phase I clinical trial in patients with solid tumors (including breast, prostate, pancreatic cancers and inflammatory breast cancer) and a separate Phase I trial in patients with multiple myeloma has recently been initiated.  During the solid tumor trial, CX-4945 has established favorable pharmacokinetic, pharmacodynamic and safety profiles.  Measurement of mechanism and tumor-related biomarkers in patients reveal that CX-4945 hits the CK2 target and down-modulates the PI3K/Akt pathway.  The pharmacokinetic and biomarker data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response in humans.  Together, the findings establish CX-4945 as a promising therapeutic agent for targeting multiple cancers.

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company, discovering and developing targeted small molecule drugs to treat life-threatening cancers.  Cylene's drug discovery platform, STAND (Selective
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
2. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
3. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
4. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
5. PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santopreneā„¢ TPV Medical Grades
6. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
7. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
8. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
9. Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer
10. Greenway Selected by Health Information Exchanges and Regional Physician Groups
11. Award-Winning Thermal Angel Selected as Winner for Outstanding Military Product of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/16/2014)... marvel of the embryo. It begins as a glob of ... to become the cells of our lungs, muscles, nerves and ... in a feat of reverse tissue engineering, Stanford University researchers ... embryonic cells to proliferate and transform into all of the ...
(Date:4/16/2014)... Therapeutics, Inc. (NASDAQ: CLDX) announced today that final data ... tumors, including long-term patient follow-up, have been published in ... The data demonstrate robust antibody and T cell responses ... advanced cancers and suggest that CDX-1401 may predispose patients ...
(Date:4/16/2014)... DOWNERS GROVE, Ill. April 16, 2014 According ... surveillance colonoscopy in average-risk patients with one to two ... 90 percent of cases. This may be an appropriate ... endoscopic database study to quantify adherence to guidelines for ...
(Date:4/15/2014)... Cases of diabetes and pre-diabetes in the United States have ... Hopkins Bloomberg School of Public Health, with obesity apparently to ... burden of the disease has not hit all groups equally, ... elderly. , According to new research reported in the April ...
(Date:4/15/2014)... solved a decades-old medical mystery and in the process have ... which kill about 1.5 million people a year. The researchers say ... drug that has been in use for more than 50 years ... as it is to the microbes it attacks. , A ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... , WEDNESDAY, Jan. 4 (HealthDay News) -- Remember those ... but you took the plunge and whizzed downward. Next, ... and hanging by your knees at the pinnacle. ... sliding boards, safer plastic climbers and fence-protected platforms are ...
... CareFirst BlueCross BlueShield (CareFirst) today announced that it has ... make available the ACP,s Medical Home Builder 2.0 ... (PCMH) practices. The ACP developed MHB 2.0 as ... care, organization, and workflow. CareFirst is making the ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... in the United States are far more likely to be ... 16 other countries, a new study indicates. Researchers suspect ... days in the United States compared with at least six ...
... -- The current issue of Medical Acupuncture , ... explores how the U.S. military is incorporating medical acupuncture ... serving in the war zones and the efforts underway ... available online at http://www.liebertpub.com/acu . "The use ...
... pharmaceutical industry continues to globalize, the challenges of securing ... as well as the consequences of lapses in security ... encourage comprehensive public standards across the pharmaceutical industry, the ... recommended best practices that will help ensure that medicines ...
... of two substances in licorice used extensively in Chinese ... tooth decay and gum disease, the leading causes of tooth ... Journal of Natural Products , they say that these ... decay and gum disease. Stefan Gafner and colleagues ...
Cached Medicine News:Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 3Health News:CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes 2Health News:CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes 3Health News:U.S. Heart Attack Patients Readmitted Most Often: Study 2Health News:U.S. Heart Attack Patients Readmitted Most Often: Study 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: